PharmAthene says Army completed recombinant bioscavenger testing PharmAthene announced that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the company's recombinant butyrylcholinesterase bioscavenger demonstrating that it successfully targets and binds to a broad spectrum of nerve agents, including sarin and tabun, which are believed to be part of the Syrian chemical weapons inventory.
News For PIP From The Last 14 Days
Check below for free stories on PIP the last two weeks.
PharmAthene receives notice advising company of of SparVax anthrax vaccine PharmAthene announced that it has received notice from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority, advising the company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax program. PharmAthene has been developing SparVax to address a requirement for a modern anthrax vaccine based on state-of-the-art vaccine technology. Phase 1 and Phase 2 clinical trials involving 770 healthy subjects have demonstrated that SparVax appears to be well tolerated and capable of producing an immune response in humans.